{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=42", "query": { "intervention": "placebo", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 4150, "total_pages": 415, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=41&page_size=10" }, "source": "local", "last_synced_at": "2026-10-20T22:15:51.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06716021", "title": "ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Etripamil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milestone Pharmaceuticals Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2026-08-20", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-13T21:27:10.162Z", "location_count": 4, "location_summary": "West Hills, California • Littleton, Colorado • Haddon Heights, New Jersey + 1 more", "locations": [ { "city": "West Hills", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Haddon Heights", "state": "New Jersey" }, { "city": "Manhattan", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06716021" }, { "nct_id": "NCT06672549", "title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 125, "start_date": "2024-11-18", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-20T22:15:51.533Z", "location_count": 50, "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672549" }, { "nct_id": "NCT06338995", "title": "A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "LY3650150", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard therapy for INCS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 510, "start_date": "2024-04-29", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-14T01:29:20.741Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06338995" }, { "nct_id": "NCT06143956", "title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "LY3305677", "type": "DRUG" }, { "name": "LY3532226", "type": "DRUG" }, { "name": "LY3549492", "type": "DRUG" }, { "name": "LY3841136", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1481, "start_date": "2023-11-17", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-13T19:56:10.614Z", "location_count": 49, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06143956" }, { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-20T16:28:45.851Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT05923606", "title": "Modulation of Brain Oscillations Underlying Working Memory", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Working Memory" ], "interventions": [ { "name": "Active tACS", "type": "DEVICE" }, { "name": "Placebo tACS", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 32, "start_date": "2024-07-10", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-08T00:17:55.223Z", "location_count": 1, "location_summary": "Charlestown, Massachusetts", "locations": [ { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923606" }, { "nct_id": "NCT05028829", "title": "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Liver Fibroses" ], "interventions": [ { "name": "Atorvastatin 20mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Raymond Chung", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-05-10", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T04:43:26.347Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Dallas, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05028829" }, { "nct_id": "NCT04910685", "title": "(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Indolent Systemic Mastocytosis", "Smoldering Systemic Mastocytosis" ], "interventions": [ { "name": "Elenestinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2021-11-30", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-13T19:02:15.776Z", "location_count": 15, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910685" }, { "nct_id": "NCT07861295", "title": "Satavari and Ashoka for Menopause (SAM) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Menopause" ], "interventions": [ { "name": "Ashoka Bark and Shatavari", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Vidya USA Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 50, "start_date": "2025-10-01", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-16T04:01:09.528Z", "location_count": 1, "location_summary": "New Port Richey, Florida", "locations": [ { "city": "New Port Richey", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07861295" }, { "nct_id": "NCT07860021", "title": "VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stiff Person Syndrome" ], "interventions": [ { "name": "Hytrulo-placebo (consisting of Hyaluronidase)", "type": "DRUG" }, { "name": "VYVGART Hytrulo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "25 Years to 80 Years" }, "enrollment_count": 26, "start_date": "2026-09-30", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-16T05:26:34.709Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07860021" } ] }